How long should we allow metformin to remain the bogeyman in CKD? Should MALA scare us from ever letting our patients benefit from metformin? Join us as we discuss some rare prospective data on metformin in moderate to severe CKD.
Background
This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?
Background
This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.
Background
This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.
Background
This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…
